AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements

AIkido Pharma Inc. Executes Licensing Agreement for Psilocybin for Cancer Applications

AIkido Pharma Announces Publication of Artificial Intelligence-Machine Learning Sponsored Research Program for Pancreatic Cancer

AIkido Pharma Inc. Announces Results of 2020 Annual Stockholder Meeting

AIkido Pharma Inc. Announces Publication of Favorable Peer Reviewed Study of Newly Licensed Antiviral Compounds

AIkido Pharma Inc. Provides Update on Its Next-Generation Chemotherapeutic Treatment DHA-dFdC

AIkido Pharma Announces Update On Its Use Of Artificial Intelligence

AIkido Pharma Inc. Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)

AIkido Pharma Announces Peer-Reviewed Publication of Positive Results from Study of Antiviral Compounds Licensed from University of Maryland, Baltimore

AIkido Pharma Sponsors Survival Study of University of Kentucky Anticancer Drug G4-1 in Exchange for Exclusive Option to License